This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Down -8.63% in 4 Weeks, Here's Why You Should You Buy the Dip in IDEAYA Biosciences (IDYA)
by Zacks Equity Research
The heavy selling pressure might have exhausted for IDEAYA Biosciences (IDYA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
IDEAYA Biosciences, Inc. (IDYA) Reports Q4 Loss
by Zacks Equity Research
IDEAYA Biosciences (IDYA) delivered earnings and revenue surprises of -122.39% and 0%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Sage Therapeutics, Inc. (SAGE) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Sage Therapeutics (SAGE) delivered earnings and revenue surprises of -7.59% and 11.20%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
All You Need to Know About IDEAYA Biosciences (IDYA) Rating Upgrade to Buy
by Zacks Equity Research
IDEAYA Biosciences (IDYA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wall Street Analysts Predict an 81.88% Upside in IDEAYA Biosciences (IDYA): Here's What You Should Know
by Zacks Equity Research
The consensus price target hints at an 81.9% upside potential for IDEAYA Biosciences (IDYA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Earnings Preview: Gilead Sciences (GILD) Q3 Earnings Expected to Decline
by Zacks Equity Research
Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: IDEAYA Biosciences, Inc. (IDYA) Q3 Earnings Expected to Decline
by Zacks Equity Research
IDEAYA Biosciences (IDYA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IDEAYA Biosciences, Inc. (IDYA) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
IDEAYA Biosciences (IDYA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
How Much Upside is Left in IDEAYA Biosciences (IDYA)? Wall Street Analysts Think 32.97%
by Zacks Equity Research
The mean of analysts' price targets for IDEAYA Biosciences (IDYA) points to a 33% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Biotech Stock Roundup: KYMR, IDYA, QURE Soar on Study Data, HLVX Tanks on Study Failure
by Zacks Equity Research
IDEAYA Biosciences (IDYA) and uniQure N.V. (QURE) are in the spotlight following positive pipeline updates.
IDEAYA (IDYA) Up on Upbeat Phase II Bladder & Lung Cancer Data
by Zacks Equity Research
IDEAYA (IDYA) gains 15% on positive clinical data from its phase II study evaluating the 30 mg monotherapy expansion dose of IDE397 to treat MTAP-deletion urothelial and NSCLC patients.
Company News for July 9, 2024
by Zacks Equity Research
Companies In The Article Are:MORF, LLY, IDYA, ETSY, INTC.
Strength Seen in IDEAYA Biosciences (IDYA): Can Its 15.3% Jump Turn into More Strength?
by Zacks Equity Research
IDEAYA Biosciences (IDYA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
IDEAYA Biosciences, Inc. (IDYA) Moves 7.6% Higher: Will This Strength Last?
by Zacks Equity Research
IDEAYA Biosciences, Inc. (IDYA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Can IDEAYA Biosciences, Inc. (IDYA) Climb 25.48% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for IDEAYA Biosciences, Inc. (IDYA) points to a 25.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
IDEAYA Biosciences, Inc. (IDYA) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
IDEAYA Biosciences, Inc. (IDYA) delivered earnings and revenue surprises of 2.13% and 22.98%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
IDEAYA Biosciences, Inc. (IDYA) Surges 7.6%: Is This an Indication of Further Gains?
by Zacks Equity Research
IDEAYA Biosciences, Inc. (IDYA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
IDEAYA Biosciences, Inc. (IDYA) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
IDEAYA Biosciences, Inc. (IDYA) delivered earnings and revenue surprises of 5.66% and 53.25%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Denali Therapeutics Inc. (DNLI) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of 251.16% and 2,502.86%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Frequency (FREQ) Up 77% on Merger Deal With Korro Bio
by Zacks Equity Research
Post-merger, Frequency (FREQ) focuses on advancing RNA editing programs. This combined entity is set to operate under the name Korro Bio, which will apply to trade on the NASDAQ under the ticker symbol KRRO.
IDEAYA Biosciences, Inc. (IDYA) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
IDEAYA Biosciences, Inc. (IDYA) delivered earnings and revenue surprises of 3.92% and 45.02%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Will Entera Bio Ltd. (ENTX) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Entera Bio Ltd. (ENTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IDEAYA Biosciences, Inc. (IDYA) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
IDEAYA Biosciences, Inc. (IDYA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strength Seen in IDEAYA Biosciences, Inc. (IDYA): Can Its 35.7% Jump Turn into More Strength?
by Zacks Equity Research
IDEAYA Biosciences, Inc. (IDYA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
IDEAYA Biosciences, Inc. (IDYA) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
IDEAYA Biosciences, Inc. (IDYA) delivered earnings and revenue surprises of 12.28% and 48.44%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?